Mitsubishi UFJ Asset Management Co. Ltd. Raises Holdings in Abbott Laboratories $ABT

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Abbott Laboratories (NYSE:ABT) by 1.4% in the 4th quarter, Holdings Channel reports. The firm owned 6,998,412 shares of the healthcare product maker’s stock after acquiring an additional 99,019 shares during the quarter. Abbott Laboratories accounts for about 0.6% of Mitsubishi UFJ Asset Management Co. Ltd.’s portfolio, making the stock its 24th largest position. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Abbott Laboratories were worth $869,133,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Citizens & Northern Corp lifted its stake in shares of Abbott Laboratories by 0.4% in the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after buying an additional 79 shares in the last quarter. American National Bank of Texas grew its stake in Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after acquiring an additional 79 shares in the last quarter. Nia Impact Advisors LLC raised its holdings in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after acquiring an additional 79 shares during the last quarter. Nova R Wealth Inc. lifted its stake in Abbott Laboratories by 3.0% in the 3rd quarter. Nova R Wealth Inc. now owns 2,802 shares of the healthcare product maker’s stock worth $375,000 after purchasing an additional 81 shares in the last quarter. Finally, Connable Office Inc. boosted its holdings in shares of Abbott Laboratories by 0.5% during the 3rd quarter. Connable Office Inc. now owns 15,042 shares of the healthcare product maker’s stock worth $2,015,000 after purchasing an additional 81 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.4%

Abbott Laboratories stock opened at $87.18 on Wednesday. The firm has a 50 day moving average price of $103.83 and a 200 day moving average price of $115.68. Abbott Laboratories has a fifty-two week low of $86.16 and a fifty-two week high of $139.06. The company has a market capitalization of $151.84 billion, a PE ratio of 24.42, a price-to-earnings-growth ratio of 1.46 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.9%. Abbott Laboratories’s dividend payout ratio is 70.59%.

Insider Transactions at Abbott Laboratories

In other news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. This trade represents a 2.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,055 shares of company stock valued at $353,097 over the last quarter. Insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Mizuho cut their price target on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Royal Bank Of Canada reduced their price target on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Barclays cut their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Finally, The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating on the stock in a report on Wednesday, April 8th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $119.43.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.